Nephrocare Health Services Limited (NSE:NEPHROPLUS)

Market Cap	63.09B
Revenue (ttm)	9.99B +128.4%
Net Income	768.40M
EPS	8.10
Shares Out	100.34M
PE Ratio	77.63
Forward PE	38.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,150
Open	623.50
Previous Close	635.70
Day's Range	623.50 - 646.85
52-Week Range	446.00 - 769.75
Beta	n/a
Analysts	Buy
Price Target	771.25 (+22.65%)
Earnings Date	Jul 24, 2026

About NSE:NEPHROPLUS

Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India.

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 2009
• Employees: 3,448
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NEPHROPLUS

Financial Performance

In fiscal year 2026, NSE:NEPHROPLUS's revenue was 9.99 billion, an increase of 32.16% compared to the previous year's 7.56 billion. Earnings were 768.40 million, an increase of 14.52%.

Analyst Summary

According to 4 analysts, the average rating for NEPHROPLUS stock is "Buy." The 12-month stock price target is ₹771.25, which is an increase of 22.65% from the latest price.

Price Target

₹771.25

(22.65% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 21, 2026

Data Sources Report a data error